Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Janssen Exec On Speeding Earlier Myeloma Interventions To Market With Key Biomarker

Jun 04 2018

• By Eleanor Malone

Janssen hopes regulators will help speed its plow with new myeloma surrogate endpoint

Related Content

Minimal Residual Disease 'Coming Soon' As An Approval Endpoint, Celgene Says

Dec 13 2017

Amgen's Postmarketing Trials For Blincyto Likely To Form Stringent Dataset On Minimal Residual Disease

Apr 05 2018

Bluebird's BCMA CAR-T Sings At ASCO, But How Will It Fly In Early Multiple Myeloma?

Jun 02 2018

Cancer Trial Endpoints: Minimal Residual Disease Eyed As Surrogate

Sep 21 2016

Related Companies

Johnson & Johnson

Genmab A/S

Genetix Biotherapeutics

Bristol Myers Squibb Company

Additional Topics

Clinical Trials Drug Review Regulation Review Pathway Cancer Blood & Coagulation Disorders BioPharmaceutical ASCO

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window